DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 1 -  
  
CLINICAL  TRIAL  PROTOCOL:  V3011902  
 
Protocol Number:  V3011902  
 
Protocol Date:  Original Protocol (Version  1.0)/ 8 March  2021  
Protocol Amendment 1 (Version 2.0)/27 April 2021 
Protocol Amendment 2 (Version 3.0)/12 May 2021 Protocol Amendment 3 (Version  4.0)/ [ADDRESS_837719] 2021 
Protocol Amendment 4 (Version  5.0)/ 10 September  2021  
Protocol Amendment 5 (Version  6.0)/ 9 January  2022  
Protocol Amendment 6 (Version  7.0)/ 18 March  2022  
 
Protocol Title:  Phase 3, Randomized, Placebo -Controlled, Efficacy  and Safety  Study 
of VERU -111 for the Treatment of Severe Acute Respi[INVESTIGATOR_81370] 2 (SARS-CoV-2) in Patients at High Risk for Acute Respi[INVESTIGATOR_39053] (ARDS). 
 
IND number:  [ADDRESS_837720]  number:  2021- 001194 -24 
Clinical Phase:  3 
 
Study  Sponsor:  Veru  Inc. 
[ADDRESS_837721] Miami,  FL [ZIP_CODE]  
Telephone: (305) 509- 6986  
 
 
 
 
 
 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837722]  POPULATION .................................................................................. 18 
6.1 Number of Subjects  ............................................................................................... 18 
6.2 Selection  Criteria  ................................................................................................... 18 
6.2.1 I
nclusion Criteria  ................................................................................................... 18 
6.2.2 Exclusion Criteria  .................................................................................................. 19 
7.0 STUDY MEDICATION ...................................................................................... 20 
7.1 Enrollment and  Blinding ....................................................................................... 20 
7.2 Drug  Supply  .......................................................................................................... 20 
7.2.1 VERU-111 Capsules .............................................................................................. 20 
7.2.2 Placebo  Control  ..................................................................................................... 20 
7.2.3 Drug  Accountability  .............................................................................................. 21 
7.3 Drug  Administration  .............................................................................................. 21 
8.0 STUDY PROCEDURE S ..................................................................................... 21 
8.1 Screening  ............................................................................................................... 21 
8.2 Enrollment  ............................................................................................................. 22 
8.3 Day 1 ..................................................................................................................... 22 
8.4 Day 2 through Day  21 or day of discharge from  the hospi[INVESTIGATOR_307] (whichever  
comes  first)  ............................................................................................................ 23 
8.5 Day 3, Day 9, and  Day 15 .....................................................................................
 23 
8.6 Day 22 ± 3 days (these assessments  will also be done at Early  Termination  
from  the study)  ...................................................................................................... 23 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 3 -  
 8.7 Day 29 ± 3 days  ..................................................................................................... 24 
8.8 Follow up visits at Day 45 (± 3 days) and Day 60 (± 3 days) (conducted via 
phone/teleconference)  ............................................................................................ [ADDRESS_837723] Medication  Causality  ..................................................................................... 27 
8.11.3 Serious Adverse Events  ......................................................................................... 28 
8.11.4 Initial Reports  ........................................................................................................ 29 
8.11.5 Precautions  ............................................................................................................ 29 
8.11.6 Reporting of Adverse Events Associated with Study Drug Overdose, Misuse, Abuse or Medication  Error .................................................................................... 29 
8.12 Concomitant Medications  and Concomitant Therapi[INVESTIGATOR_014]  ......................................... 30 
8.13 Prohibited Medications  .......................................................................................... 30 
8.14 Pharmacokinetic Sampling  and Handling  ............................................................. 30 
8.15 Plasma  Sample  Labels  for Pharmacokinetic Samples  ........................................... 31 
9.0 STATISTICAL  ANALYSIS  ............................................................................... 31 
9.1 Sample  Size Calculation  ........................................................................................ 31 
9.2 Analysis Sets.......................................................................................................... 32 
9.3 A 
nalysis Scope  ...................................................................................................... 32 
9.4 Efficacy  Analyses  .................................................................................................. 33 
9.4.1 Primary  Endpoint  .................................................................................................. 33 
9.4.2 Secondary  Analyses  of the Primary  Endpoint  ....................................................... 33 
[IP_ADDRESS] Sensitivity  Analyses  .............................................................................................. 33 
9.5 Secondary  Endpoint ............................................................................................... 34 
9.5.1 Proportion of patients  alive  and free of respi [INVESTIGATOR_628607] 29, Day 15 
and Day 22 ............................................................................................................. 34 
[IP_ADDRESS] Days  in ICU  ........................................................................................................... 34 
[IP_ADDRESS] Change from  baseline in WHO  Ordinal Scale for Clinical Improvement at Day  15, 
Day 22 and Day 29 ................................................................................................ 35 
[IP_ADDRESS] Days  on mechanical  ventilation  ............................................................................. 36 
[IP_ADDRESS] Days  in hospi[INVESTIGATOR_307]  ..................................................................................................... 36 
[IP_ADDRESS] Mean  chan ge from  baseline in Viral  load  to Day  9 ............................................... 36 
9.6 Pharmacokinetic  Analysis  ..................................................................................... 36 
9.7 Safety  Analysis  ...................................................................................................... 36 
9.7.1 Independent Dat a Monitoring Committee  (IDMC) ............................................... 37 
9.7.2 I
nterim Analysis  .................................................................................................... 37 
10.0 ADMINISTRATION PROCEDURES  ..............................................................
 38 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837724]  Keepi[INVESTIGATOR_007]  ..................................................................................................... 41 
10.6 Data Quality  .......................................................................................................... 41 
10.7 Regulatory Approval  ............................................................................................. 41 
10.8 Publication  Policy  .................................................................................................. 42 
10.9 Clinical Study Report  ............................................................................................ 42 
10.10 Contractual  and Financial  Details  ......................................................................... 42 
10.11 Insurance and Indemnity ........................................................................................ 43 
11.0 REFERENCES  .................................................................................................... 43 
12.0 APPENDICES  ..................................................................................................... 45 
12.1 Appendix A: Clinical Laboratory Tests  (local  laboratory)  .................................... 45 
12.2 A
ppendix B: Schedule of Study Evaluations  ........................................................ 46 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837725]  
IUD Intrauterine device  
IUS Intrauterine system  
LAR  Legally  Authorized Representative  
LDH Lactate  dehydrogenase  
LDL Low density lipoprotein  
LMWH  Low molecular weight heparin  
MedDRA  Medical  dictionary of regulatory activities  
NSAID  Nonsteroidal anti-inflammatory drug 
OTC  Over  the Counter  
PRN Pro re nata  – As  Needed  
RRT Renal replacement  therapy  
SAE Serious adverse event  
SAP Statistical analysis  plan 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 6 -  
 2.0 PHASE  3 PROTOCOL  SUMMARY  
 
Study 
Number:   
V3011902  
Title:  Phase  3, Randomized,  Placebo -Controlled,  Efficacy  and Safety  Study  of 
VERU-111 for the Treatment of Severe Acute Respi[INVESTIGATOR_98189] 2 (SARS-CoV-2) in Patients at High Risk for Acute Respi[INVESTIGATOR_39053] (ARDS) 
 
Primary 
Objectives:  To demonstrate  the efficacy  of VERU -[ADDRESS_837726] on the  proportion of patients who die  on 
study (prior to Day 60). 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 7 -  
  
Secondary 
Objectives:  The secondary  objectives/endpoints  on this study  are: 
 
1. The proportion of subjects  that are alive  without respi[INVESTIGATOR_628608] 15, Day 22 and Day 29. Day 29 is the key secondary 
endpoint in this study. Respi[INVESTIGATOR_628609] m echanical  ventilation,  extracorporeal 
membrane oxygenation, high-flow nasal cannula oxygen delivery, noninvasive positive pressure ventilation, clinical diagnosis of respi[INVESTIGATOR_628610].  
2. Days  in ICU  
3. WHO  Ordinal  Scale  for Clinical Improvement change from 
baseline to Day 15, Day 22, and Day 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Days  on mechanical  ventilation  
5. Days  in hospi[INVESTIGATOR_307]  
6. Proportion of subjects  that die on study at Day 15, Day 22, and Day 
29. 
7. Change  from  baseline  in viral load (baseline  to Day 9) 
Safety 
Objective:  To assess  the safety,  tolerability,  and risk/benefit  of VERU -111 Patient  State  Descriptor  Score  
Uninfected  No clinical  or virological  evidence 
of infection  0 
Ambulatory  No limitation  of activities  1 
 Limitation  of activities  2 
Hospi[INVESTIGATOR_057],  Mild  disease  Hospi[INVESTIGATOR_057],  no oxygen  therapy  3 
 Oxygen  by [CONTACT_628632]  4 
Hospi[INVESTIGATOR_057],  Severe 
disease  Non-invasive  ventilation  or high- 
flow oxygen  5 
 Intubation  and mechanical 
ventilation  6 
 Ventilation + additional organ 
support  – pressors,  RRT, ECMO 7 
Death  Death  8 
 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 8 -  
  
Design:  This study is a multicenter, randomized, placebo -control, efficacy and 
safety  study of VERU-[ADDRESS_837727]  from  screening  to follow up visit is 
planned to be 62 days. 
 
In addition to the safety of VERU-111, an evaluation of the efficacy of 
VERU-111 on SARS -CoV-2 (COVID -19) compared  to the placebo  control 
will be evaluated as part of the Independent Data Monitoring Committee (IDMC).  
Subjects:  Approximately, 210 subjects are planned to be randomized at a 2:1 ratio 
into two treatment  arms  (140 subjects  in the VERU-111 treated  group and 
70 subjects in the Placebo treated group). 
 
Randomization will be stratified  by [CONTACT_628633] 
4, 5 and 6 such that subjects with a WHO Ordinal Scale of 4, 5 and 6 at baseline are approximately equally distributed between the treatment groups.  
 
NOTE:  Throughout this protocol the terms  “patients”  and “subjects” are 
used interchangeably.  
Treatments:  Subjects in the VERU -[ADDRESS_837728].  
Procedures:  Potential study participants will undergo a series of screening evaluations, 
including the collection  of demographic information, within  3 days prior to 
randomization. Subjects  who give written  informed  consent and satisfy  the 
selection criteria will be enrolled into the study.  
 
SpO 2 levels  will be taken  at screening,  baseline  (Day  1) and on Days  3, 9, 
15, 22, and 29. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 9 -  
  
 Safety  evaluations  including  assessment  of adverse  events  (Days  1-22, Day 
29, Day 45, and Day 60), 12-lead electrocardiogram (single) (screening, 
Day 15, Day 22, and Day 29) and clinical laboratory results: urinalysis (screening, baseline, Day 22, and Day 29), hematology (screening, 
baseline,  Day 3, Day 9, Day  15, Day 22, and  Day 29), and serum  chemistry  
(screening, baseline,  Day 3, Day 9, Day 15, Day 22 and Day 29). 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 10 -  
 3.0 INTRODUCTION  
 
3.1 Background  
Severe Acute Respi[INVESTIGATOR_7531] 2 (SARS-CoV-2) is an enveloped, 
nonsegmented, positive-sense, single stranded RNA virus with an unusually large RNA genome, a nucleocapsid, and club-like spi[INVESTIGATOR_2988] (S protein) that project from their surface and from which they are named. It belongs to the betacoronavirus category which includes SARS -CoV and MERS-CoV. These viruses have been responsible for epi[INVESTIGATOR_628611]- respi[INVESTIGATOR_628612], highly 
contagious, and mortality rates between 10- 35% ( Cascella 2020 ). The coronavirus 
superfamily ( Coronaviridae ) includes several human pathogens with large RNA genomes, 
e.g., influenza and  viral encephalitis  and they are classified  into alpha,  beta,  delta  and gamma 
coronavirus families  and then  further divided into Lineages  A, B, C and D. SARS -CoV-2 is a 
Lineage B betacoronavirus ( Gorbalenya 2020).  
 
Starting in December 2019, SARS-CoV-2 infection resulted in Coronavirus Disease 2019 (COVID -19) and consequently has been  declared  a global pandemic with 98,050,801 cases 
and 2,098,174 deaths worldwide as of 22 January 2021 at 1:44 GMT (January 22, 2021; Worldometers.info).  
Viruses  have efficient mechanisms  that take control of their host’s cellular machinery to carry 
out viral replication, assembly and to exit from the cell to spread infectious virions. Given the spatial distances between the point of virion entry at the plasma membrane to the location in the cell where RNA replication (nucleus) and viral assembly occur in the ER and Golgi and then the newly  generated  virions have to travel  back  out to the plasma  membrane to egress  out 
of the cell, it is no wonder that the virus’s most critical task is to hijack the host’s internal transportation system, the cytoskeleton ( Ward 2011). The cytoskeleton has three major types 
of protein filaments: microfilaments (actin), microtubules (tubulin), and intermediate filaments. The principal ones involved in viral replication and trafficking (transport) are microtub ules and actin since these are the two main filament systems involved in cellular 
transport ( Ward 2011).  
Microtubules are important for cell shape, transport, motility, and cell division ( Heald 2002 ). 
Microtubules are  dynamic long polar fibers/filaments that result from the polymerization of α  
and β tubulin heterodimer  subunits with a positive end located  at the plasma  membrane and  a 
minus end  facing  the nucleus at  the microtubule organizing center  (MTOC).  From  the MTOC, 
microtubule fibers radiate out from the nuclear area towards the periphery of the cell. Microtubules are dynamic network systems,  meaning  that, they undergo  rapid polymerization 
(add α and β tubulin subunits heterodimers)  to grow,  and subsequent rapid depolymerization 
(remove α  and β  tubulin subunits heterodimers) to shrink. This “dynamic” growing and 
shrinking serves the constantly changing transportation requirements of the cell. Large macromolecules, like viruses, engage with specialized motor proteins (kinesins and dyneins) (Dohner 2005; Biswas 2014; Han 2012; Hara 2 009). Kinesins and dyneins attach, carry, and 
move the virus cargo up and down these microtubule tracks to travel long distances to reach the different compartments within the cell ( Ward 2011; Simpson 2020; Cooper 2000).  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837729] of viral replication ( Naghavi 2017; 
Dohner 2005 ). In fact, viral infection  or expression of viral proteins alters  the organization of 
the microtubular networks to serve their need to replicate and spread infectious virion. 
Microtubules not only facilitate infection, but microtubules are actively manipulated by [CONTACT_419939] ( Naghavi 2017).  Furthermore,  microtubule inhibiting  agents  that disrupt microtubule 
networks suppress viral infection ( Rudiger 2016).  
Virus -cell 
surface interactions,  virus  entry and internalization - 
Although microtubules are located  within  the cell, they  are able to influence the viral infection 
from the onset. Viruses utilize specific sites and proteins to attached to the cell surface. The spatial organization of these surface receptors and entry factors are controlled in part by [CONTACT_628634] ( Naghavi 2017). When added early, nocodazole, a 
microtubule depolymerizing drug, decreased mouse hepatitis coronavirus virus infection by [CONTACT_419941] ( Burkard 2014). There are apparently other 
ways that entry and internalization may occur as human coronavirus NL63 internalization and vesicle entry was not affected by [CONTACT_419942] ( Mile wska 2018).  
In the case of SARS -CoV, the first stage of interaction with the microtubule cytoskeleton 
occurs  when  the Spi[INVESTIGATOR_2531] (S) protein mediated  attachment  to the cell surface  (Ren 2015).  After 
binding, the virus particles actively rearrange the cytoskeleton by [CONTACT_628635]/Cofilin/Rac/Cdc42 pathway ( Lv 2019 ). 
Virus  intracellular  
 transport via microtubules to the perinuclear region - 
Many  viruses require  microtubules at cell entry  for efficient  nuclear  targeting  (Dohner 2005). 
Vesicular transport occurs via microtubule trafficking and the corresponding specialized motor proteins. In the case of the Mouse Hepatitis Coronavirus Virus, the early secretory pathway is important in the formation of the replication complex ( Knoops 2010; Oostra  
2007). Intracel lular transport of the endocytosed vesicles containing coronavirus utilizes S- 
protein bound to β- tubulin on microtubules to locate to the perinuclear region of the cell. 
Viruses can also modulate microtubular dynamics to promote rapid transport to nucleus (Naghavi 2017; Suomalainen 2001).  Coronaviruses may also have interactions of S proteins 
with the specialized motor proteins like kinesins and dyneins ( Rudiger 2016).  
Virion  replication  
 and assembly and egress  of infectious  viral  particles  out of the cell- 
Virus particle  assembly occurs in the ER- Golgi intermediate compartment (ERGIC) and is 
orchestrated  by [CONTACT_941] M protein. M provides the scaffold  for virion morphogenesis and M-S and 
M-N interactions facilitate the recruitment of structural components to the assembly site.  
Coronavirus particles budding into the ERGIC are transported in smooth walled vesicles and trafficked via microtubules for release by [CONTACT_15334]. Host factors, specifically, the interactions between the cytoskeleton and other structural proteins are essent ial in this 
process. Interactions between tubulin and the cytosolic domain of the S protein of human coronavirus-229E, human coronavirus-NL63, and TGEV  are required  for successful  assembly 
and release of viral particles (Reviewed in Fung 2019). RNA  viruses utilize  diverse structures 
within the cytoskeleton for their replication which rely on microtubules to form and function (Naghavi 2017). Nocodazole, a microtubule depolymerizing agent, blocks the movement and 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 12 -  
 fusion of capsids and nucleoprotein particles  to the budding ER/Golgi compartments  to form 
virions as well as the secretory microtubule trafficking to egress new virions resulting in 
reduced virus yields ( Eichwald 2012; Criglar 2014; Dohner 2005).  
To evaluate early assembly events, alpha (HCoV -229E, HCoV-NL63, and TGEV) and beta 
(SARS -CoV) coronaviruses S proteins were treated with nocodazole. The pharmacological 
action  of nocodazole is the inhibition  of tubulin polymerization. Untreated  cells had long and 
filamentous  tubulin structures  (microtubules) and the  S protein accumulated  near the nucleus 
(ERGIC) and less S protein distributed in the cytosol, whereas the nocodazole treated cells had dispersed and patchy tubulin fragments and the S proteins w ere “differentially 
distributed”, or scattered throughout the cytoplasm ( Rudiger 2016). Also, following 
nocodazole treatment, M protein amount was decreased and there was a reduced colocalizat ion of S and M proteins ( Rudiger 2016). Nocodazole treatment resulted in both a 
significant reduction in viral particles and these particles had very little S protein, and thus, the virions we re less infectious as well ( Rudiger 2016). In fact, nocodazole treatment at all 
time points resulted in significantly lower virus titers in cell culture supernatant versus untreated infected cells ( Rudiger 2016).  
In summary, tubulin interacts with the cytoplasmic domain of alphacoronavirus and betacoronavirus SARS -CoV spi[INVESTIGATOR_2531] S proteins. Rudiger et al. ( 2016) conclude that the 
reduction in infectious virus titer following treatment with a drug that causes microtubule depolymerization is mainly because there is less S protein present at the ass embly site due to 
impaired S protein -microtubule  transport and that the incorporation process of S protein itself 
into virions is tubulin -dependent. Furthermore,  disruption of microtubule trafficking  impaired 
the egress  of these poorly assembled  virions with less surface  spi[INVESTIGATOR_2531] S proteins, less infectious, 
out of the cell. A microtubule depolymerizing agent may be effective in treating in treating coronavirus infection to disrupt microtubule trafficking critical for virus replication cycle. 
 
Colchicine- like Activity  
The central mechanism of colchicine clinical anti -inflammatory and anti- viral activities is 
based on its ability to bind the “colchicine binding” sites on alpha and beta tubulin which when incorporated into microtubule block subsequent microtubule polymeri zation 
(Slobodnick 2018). Inhibition of tubulin polymerization is responsible for the effects of 
colchicine on cell migration, cytokine release, and intracellular trafficking (antiviral) and disruption of inflammatory cell activities seen for a cute gout and familial Mediterranean 
fever.  Colchicine  modulates leucocyte mediated  inflammatory  activities  including inhibition 
of leucocyte production of superoxides and release of various cytokines and pyrogens (Slobodnick 2018). Colchicine- like agents may be useful to treat the “cytokine storm” seen 
with SARS -CoV 2. IL- [ADDRESS_837730] been associated with macrophage activation syndrome 
and poor clinical outcomes in severe inflammatory and septic shock conditions ( Verweyen  
2020). Interestingly, colchicine abrogates IL-1β  and IL-18 overexpression by [CONTACT_419944]. Verweyen et al. ( 2020) also 
showed that colchi cine as well as nocodazole abrogated IL -18 expression confirming that 
microtubule depolymerization is the mechanism.  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 13 -  
 3.2 Target  Indication and Pharmacologic Activity  
VERU-111 is orally  bioavailable bis-indole that binds the “colchicine binding site” of α and β 
tubulin and inhibits tubulin polymerization at low nanomolar concentrations. VERU-111 is 
neither a substrate for MDRs including P-gp, MRPs, and BCRP, nor CYP3A4. VERU-111 
also decreases the transcription of β I, βIII, and β IV-tubulin isoforms ( Li 2012). VERU -[ADDRESS_837731] failed an androgen receptor targeting ag ent. 
 
3.3 Study  Rationale  
In a Phase 2, double-blind, placebo -controlled clinical  study the safety  and efficacy  of VERU- 
111 in the treatment of SARS-CoV-2 in patients at high risk for ARDS was assessed. Thirty- 
nine (39) hospi[INVESTIGATOR_628613] 18 mg of VERU- 111 (powder in capsule formulation) or matching placebo. The primary efficacy endpoint for the study was the proportion of patients alive without respi[INVESTIGATOR_226284] 15, Day 22, and Day 29. The key secondary endpoints in the study were days on mechanical ventilation, days in intensive care unit (ICU), and proportion of patients discharged from the hospi[INVESTIGATOR_52965] 15, Day  22, and Day 29. The  efficacy conclusions in  the Intent- to-Treat  (ITT)  population 
from a post-hoc analysis from the Phase 2 study are: 
 
• VERU-111 reduced  the proportion of patients  who died on study (up to Day 60)  from 
30% (6/20) in  the placebo  group to  5% (1/19) in  the VERU-111 treated  group. This  is 
an approximately 82% reduction in mortality in the VERU -111 treated group.  
• VERU-111 reduced the proportion of patients that are treatment failures, i.e. death or respi[INVESTIGATOR_628614]  35.0% in the placebo  group to 15.8% in the VERU-111 treated 
group at Day 15 and from 30.0% in the placebo group to 10.5% in the VERU-111 treated group at Day 29. This represents an approximately 55% reduction in treatment failures at Day 15 and a 65% reduction in treatment failures at Day 29 in the VERU- 111 treated group compared to placebo.  
• VERU-111 reduced  the days on mechanical  ventilation  from  an average of 5.4 days in 
the placebo group to 1.6 days in the VERU-111 treated group. This represents a 3.4- fold increase in the days on mechanical ventilation in the placebo group compared to the VERU -111 treated group. 
• VERU-111 reduced  the days in ICU from  an average of 9.6 days in the placebo  group 
to 3.0 days in the VERU-111 treated group. This represents a 3.2-fold increase in the days in the ICU in the placebo group compared to the VERU-111 treated group. 
• There is an imbalance  in the gender distribution  between  the treatment  group such that 
the placebo group is 85% male (17/20) and the VERU-111 treated group is 53% male (10/19). This imbalance was evaluated  as a covariate in the analysis  but did not have a 
significant effect on the conclusions of the study. 
• The 
use of remdesivir  and dexamethasone did not have a significant effect  on patient 
outcomes in the study. 
• In patients with a WHO disease severity score of ≥5 at baseline, the proportion of patients  that died on study  (up to Day 60) in the placebo  group was  46% compared  to 
10% in the VERU-111 treated  group. This  represents a 78% reduction in death in the  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 14 -  
 VERU-111 treated  group compared  to placebo. It  is important to note that in the Phase 
2 study, the 6 patients in the placebo group and the 1 patient in the VERU-111 treated 
group that died on study all had a WHO disease severity score of ≥[ADDRESS_837732] a WHO disease severity score of 4, 5, and 6 a t 
baseline are approximately equally  distributed  between  the treatment groups. This is a 
similar population as was used in the Phase 2 study and accounts for patients that move from WHO severity score of 4 to 5 and then from WHO severity score of 5  to 6 
to 7 quickly. 
 
The Phase 2 clinical study was hypothesis generating. A 78-82% reduction in mortality, a 55- 
65% reduction in death or respi[INVESTIGATOR_1399], 3.2-fold higher mean days in ICU and 3.4-fold higher mean  days on mechanical  ventilation  in the Placebo  group compared  to the VERU-111 
treated group are all clinically relevant observations and warrant the continued development of VERU -111 in the treatment of SARS-CoV-2 in patients at high risk for ARDS. 
 
There were no  drug related  serious adverse events  (SAEs) observed in  the Phase 2 clinical 
study of VERU-111 in  SARS -CoV-2 infected  patients.  There were no drug  related  serious 
adverse reactions (≥Grade 3).  
 
The relative  bioavailability  (pharmacokinetics) of the VERU-111 powder in capsule (PIC) 
formulation has been assessed and compared to a to-be- marketed VERU -111 formulated 
capsule ( FC) formulation. Additionally, the effect of high fat meal (food effect) was also 
assessed for both formulations. The data are presented in Table 1. 
 
Table 1  The Steady  State  Pharmacokinetics  of VERU-111 Powder in Capsule  (PIC) 
and Formulated Capsule (FC) Under Fasted and Fed Conditions  
 
 63 mg PIC (fasted)  63 mg PIC (fed) 31.5 mg FC  (fasted)  31.5 mg FC  (fed) 
N 6 6 6 6 
Cmax  (ng/mL)  148.1±64.7  97.8±53.5  182.2±32.6  169.9±104.2  
Tmax  (hr) 2.17±0.98  7.67±2.66  1.67±1.21  4.08±2.69  
AUC 0-24h (ng*hr/mL)  1006.16±376.29  984.80±519.62  973.58±307.87  1011.27±512.54  
T½ (hr) 7.38±4.59a 5.06±1.53b 5.11±1.24  4.89±1.09c 
AUC = area under the curve;  FC = formulated capsule;  PIC = powder  in capsule.  
a. One patient  had an aberrant  T½ of 16.09 hours.  If this value is removed from the analysis,  then the T½ is 5.64  hours 
(±1.90)  
b. The terminal  T½ was calculable in [ADDRESS_837733]  in the 31.5 FC fed group.  
 
The conclusions from  this study are: 
 
1. The T1/[ADDRESS_837734]  on 
the AUC 0-24 or Cmax at steady state. However, the shape of the curve appears to be  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837735] to food. 
 
3. The relative  bioavailability  of the VERU-111 FC formulation  compared  to the VERU-111 
PIC formulation shows that a 31.5 mg dose of the VERU-111 FC formulation shows 
similar  pharmacokinetics compared  to the 63 mg  dose of the VERU-111 PIC formulation. 
The dose of VERU-111 PIC used in the Phase 2 study was 18 mg. Therefore, for the VERU-111 dose for treatment of SARS-CoV-2 in patients at high risk for ARDS, a 9 mg dose of VERU-111 FC will be used. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837736] on the proportion of subjects that die on study (up to Day 60). 
 
4.2 Secondary  Objectives  
The secondary objectives/endpoints on this study are: 
 
1. The proportion of subjects  that are alive  without respi[INVESTIGATOR_628607]  15, Day 22, 
and Day 29. Day 29 is the key secondary endpoint. Respi[INVESTIGATOR_419908], extracorporeal membrane oxygenation, high-flow nasal cannula oxygen delivery, noninvasive positive pressure ventilation, clinical diagnosis of respi[INVESTIGATOR_628610]. 
2. Days  in ICU  
3. WHO  Ordinal Scale for Clinical Improvement change from  baseline to Day 15, Day 
22, and Day 29 
Patient  State  Descriptor  Score  
Uninfected  No clinical  or virological  evidence 
of infection  0 
Ambulatory  No limitation  of activities  1 
 Limitation  of activities  2 
Hospi[INVESTIGATOR_057],  Mild  disease  Hospi[INVESTIGATOR_057],  no oxygen  therapy  3 
 Oxygen  by [CONTACT_628632]  4 
Hospi[INVESTIGATOR_057],  Severe 
disease  Non-invasive  ventilation  or high- 
flow oxygen  5 
 Intubation  and mechanical 
ventilation  6 
 Ventilation + additional organ 
support  – pressors,  RRT, ECMO 7 
Death  Death  8 
 
4. Days  on mechanical  ventilation  
5. Days  in hospi[INVESTIGATOR_307]  
6. Proportion of subjects  that die on study at Day 15, Day 22, and Day 29. 
7. Change from  baseline in viral  load (baseline to Day  9) 
 
4.3 Safety  Objective  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 17 -  
 To assess the safety,  tolerability,  and risk/benefit of VERU- 111 
 
5.0 STUDY DESIGN 
 
5.1 Treatment  Groups  and Allocation of Subjects  
 
This randomized, placebo -control clinical  study consists of two treatment  arms:  VERU-111 9 
mg treated group, and Placebo treated group. Subjects will be randomized in a 2:[ADDRESS_837737]  of care for the treatment of SARS -CoV-2 infection 
(COVID -19). 
 
Randomization will be stratified  by [CONTACT_628636] 4, [ADDRESS_837738] in the study receive 9 mg daily oral dose of VERU- 111 or placebo for up to 21 days (Day 21) or until the patient is discharged from the hospi[INVESTIGATOR_307] (whichever comes  first) with  efficacy  and safety  follow up continuing to Day [ADDRESS_837739] in the study from screening to follow-up visit (approximately Day 60 on study) will be approximately 62 days. 
 
5.3 Efficacy  Endpoints  
 
5.3.1 Primary  Endpoint  
 
The primary  endpoint for the study is the proportion of subjects  that die on study (up to Day 
60). 
 
5.3.2 Secondary  Endpoints  
 
The secondary endpoints on this  study are:  
 
1. The proportion of subjects  that are alive  without respi[INVESTIGATOR_628607]  15, Day 22, 
and Day 29. Day 29 is the key secondary endpoint. Respi[INVESTIGATOR_628615], extracorporeal membrane 
oxygenation, high-flow nasal cannula oxygen delivery, noninvasive positive pressure ventilation, clinical diagnosis of respi[INVESTIGATOR_628610]. 
2. Days  in ICU  
3. WHO  Ordinal Scale for Clinical Improvement change from  baseline to Day 15, Day 
22, and Day 29 
4. Days  
on mechanical  ventilation  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 18 -  
 5. Days  in hospi[INVESTIGATOR_307]  
6. Proportion of subjects  that die on study at Day 15, Day 22, and Day 29. 
7. Change from  baseline in viral  load (baseline to Day  9) 
 
6.[ADDRESS_837740]  POPULATION 
 
6.1 Number  of Subjects  
Approximately 210 subjects  are planned  to be randomized  at a 2:1 ratio into two treatment 
arms (approximately 140 subjects in the VERU-111 treated group and approximately 70 
subjects in the Placebo treated group). 
 
6.[ADDRESS_837741]:  
 
1. Provide informed  consent  from  the subject  or the subject’s  Legally  Authorized 
Representative (LAR)  
2. Aged  ≥18 years  
3. Severe Acute Respi[INVESTIGATOR_349360] (SARS -CoV-2) infection  confirmed  by 
[CONTACT_940] (PCR) test  
4. Patients with a WHO Ordinal Scale for Clinical Improvement score of [ADDRESS_837742] one of the known comorbidities  for being at high risk,  such as, 
Asthma (moderate to severe), Chronic Lung Disease, Diabetes, Hypertension, Sever e 
Obesity (BMI ≥40), 65 years of age or older, primarily reside in a nursing home or long- 
term care facility, or immunocompromised and patients with a WHO Ordinal Scale for Clinical Improvement score of 5 or 6 regardless of presence of comorbidities. 
5. WHO  Ordinal Scale for Clinical Improvement score  of 4 (Oxygen by [CONTACT_628637]), 5 (Non-invasive ventilation or high-flow oxygen) or 6 (Intubation and mechanical ventilation)  
6. Peripheral  capi[INVESTIGATOR_357979]  (SpO
2) ≤ 94% on room air at screening.  If patient 
is on oxygen therapy at the time of presentation for screening and the SpO 2 levels were  
≤94% prior to introduction to oxygen therapy with proper documentation example EMT notes or ER/ED notes, then the patient is considered to have met this inclusion criterion. 
If patient is on oxygen therapy at the time of presentation for screening and the SpO
[ADDRESS_837743] met this inclusion criterion if oxygen therapy is removed and the 
SpO 2 levels fall to ≤94%, then the patient is considered to have met this inclusion 
criterion.  However,  removal  of the oxygen therapy  should only be done if it is considered 
medically reasonable.  
7. Subjects  m ust agree to follow doctor’s recommendation  for oxygen supplementation.  
8. Subjects  must agree to use acceptable methods of contraception:  
• If female of childbearing potential or a male subject’s partner could become 
pregnant, use acceptable methods of contraception from the time of the first administration  of study medication  until 6 months following administration  of 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837744] dose of study medication. Acceptable methods of contraception are as 
follows: Condom with spermicidal  foam/gel/film/cream/suppository  [i.e., barrier 
method of contraception], surgical sterilization (vasectomy with documentation of azospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pi[INVESTIGATOR_3353]), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository)  
• If the female partner of a male  subject  has undergone documented tubal ligation 
(female sterilization), a ba rrier method (condom used with spermicidal 
foam/gel/film/cream/suppository) should also be used 
• If female partner of a male subject has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository)  should also be used 
9. Subject  is willing  to comply with the requirements  of the protocol through the end of the 
study  
 
6.2.2 Exclusion Criteria  
Any of the following conditions are cause  for exclusion  from  the study:  
 
1. Known  hypersensitivity or allergy  to colchicine  
2. Pregnant or currently  breast  feeding  
3. Participation in any other clinical trial of an experimental treatment for COVID -19. 
Convalescent plasma, dexamethasone and remdesivir are allowed in this study. 
4. Concurrent treatment with other experimental agents with actual or possible direct acting antiviral activity against COVID -19 is prohibited <24 hours prior to study drug dosing 
(except  standard of care).  Remdesivir,  dexamethasone and convalescent  plasma  are allowed 
in the study. 
5. Requiring ventilation + additional organ support – pressors, RRT, ECMO (WHO Ordinal 
Scale for Clinical Improvement – Score of 7). NOTE:  short term (PRN) use of pressors  is 
allowed.  
6. Alanine Aminotransferase (ALT ) or aspartate aminotransferase (AST) >3 X  upper limit of 
normal (ULN)  
7. Total  bilirubin > ULN 
8. Creatinine  clearance < 60  mL/min  
9. Documented medical history of liver disease, including but not limited to, prior diagnosis 
of hepatitis of any etiology, cirrhosis, portal hypertension, or confirmed or suspected 
esophageal varices  
10. Moderate to severe renal impairment  
11. Hepatic impairment  
12. History  of hepatitis  (Hepatitis  B and C) NOTE:  treated  and controlled hepatitis  C is allowed.  
13. Any comorbid disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular,  gastrointestinal,  hepatic,  or central  nervous system; or in PI’s 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837745] SPF  50 on all  exposed skin and  protective clothing during prolonged sun exposure 
throughout participation in this study and/or treatment with VERU-111. 
 
7.0 STUDY MEDICATION 
 
7.1 Enrollment  and Blinding  
The study will be  a randomized,  double-blind, placebo -controlled study.  
 
Randomization will be stratified  by [CONTACT_628636] 4, 5 and 6 such that 
subjects with a WHO Ordinal Scale of 4, 5 and 6 at baseline are approximately equally 
distributed between the treatment groups. 
 
An emergency code break will be available to the investigator / pharmacist / investigational drug storage manager. This code break option in IWRS may only be disclosed in emergency situations when the identity of the trial drug must be known to the investigator in order to provide appropriate medical  treatment  or if required to assure  safety  of trial partic ipants. If  the 
code break for a patient is opened, the sponsor and CRO will be informed immediately via IWRS notification. The reason for the IWRS unblinding of the subject must be documented on the appropriate eCRF page along with the date and the initials of the person who broke the code.  
 
7.2 Drug  Supply  
7.2.1 VERU-111 Capsules  
VERU-111 9 mg dose will be supplied as capsules containing 9 mg of VERU-111. Capsules will be supplied in bottles  containing 21 capsules  in each bottle.  Patients  will take one VERU- 
111 capsule per day. 
 
The VERU -111 capsules  should be stored  at controlled room temperature,  20°C to 25°C 
(68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). 
 
7.2.2 Placebo  Control  
Placebo  capsules  containing zero (0) mg VERU-111 drug substance will be supplied in bottles 
containing 21 capsules each. These capsules are identically appearing to the VERU-111 capsules. Patients will take one Placebo capsule per day.  
 
The Placebo  capsules  should be stored  at controlled room temperature,  20°C to 25°C (68°F to 
77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837746]’s identification (i.e., subject number), the initials of the dispensing persons. Veru Inc., shall be immediately  notified  of any unexpected occurrences  during the dispensing or dosing of study 
drug.  
 
7.3 Drug  Administration  
Study drug should be taken daily at approximately the same time every day with approximately 240 mL (a full glass)  of non- alcoholic  liquid  (drink).  Dosing may be taken 
with or without food. Subjects will take the entire daily dose at once. In subjects with a 
nasogastric feeding tube, the contents of the capsules may be emptied into the tube and appropriately flushed through the tube. 
 
8.0 STUDY PROCEDURES  
 
8.1 Screening  
Potential subjects  will be screened  for this study in  the 3 days prior to enrollment. The 
following activities will be conducted at screening: 
 
1. Signed informed  consent and  HIPAA form (or legal  documents as directed  based  on the 
region outside of the [LOCATION_002]) will be obtained prior to any study- specific 
procedures and a copy of the signed consent form will be given to the subject. 
2. Assess subject  eligibility  for inclusion into this study based  on protocol 
inclusion/exclus ion criteria.  
3. Pregnancy  test (women  of childbearing potential only)  
4. Medical  history will be obtained, including diagnosis of COVID-19 infection  (date of 
diagnosis), details and dates of treatments received, documentation of symptoms related to COVID -19 infection, and COVID-19 vaccination status. 
5. WHO  Ordinal Scale score assessment  
6. The use of any medications will be recorded. This will include medications  currently 
being taken and those taken since COVID-19 symptoms started. Over-the-counter (OTC) medications  as well as medications  taken  on an as-needed  basis  (PRN) should 
be recorded.  
7. Vital signs (temperature/pulse/supi[INVESTIGATOR_050], if possible, blood pressure)  
8. SpO
2 level  (%) 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 22 -  
 9. Physical  examination  including height and  weight  
10. Electrocardiogram - 12 lead (single)  
11. Clinical Laboratory Tests  
• Hematology ( Appendix A ) 
• Serum  chemistry  (Appendix A ) 
• Urinalysis  
8.[ADDRESS_837747]  will be randomized into one of two  treatment  groups.  
 
8.3 Day 1 
The Day 1 visit assessments will serve as the baseline assessments.  
 
1. The medical  history should be reviewed  and updated  to include any changes occurring 
since the screening visit. This will include the following: 
a. Number of days from  onset of COVID -19 symptoms to Day 1 
b. Specific reason  for hospi[INVESTIGATOR_059]  
2. Assessment  of eligibility  - the WHO  Ordinal Scale  score  at Screening  will be used as 
the eligibility criteria for the study. The WHO Ordinal Scale score on Day 1 prior to 
dosing will be considered the baseline WHO Ordinal Scale score. 
3. WHO  Ordinal Scale score assessment  (prior to dosing)  
4. Pregnancy  test (women  of childbearing potential only)  
5. Vital signs (temperature/pulse/supi[INVESTIGATOR_050], if possible, blood pressure)  
6. SpO 2 level  (%) 
7. Physical  examination  (including weight)  
8. Chest  X-ray or Computed Tomography (CT) scan 
9. Viral  load 
10. Clinical Laboratory Tests  
a. Hematology ( A ppendix A ) 
b. Serum  chemistry  (Appendix A ) 
c. Urinalysis  
11. Record  the usage of any concomitant  medications and  ongoing treatments.  
12. Adverse events  (ongoing on Day 1) 
13. PK sample  prior to dosing 
14. First dose of study drug 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 23 -  
 8.4 Day 2 through Day 21 or day of discharge from  the hospi[INVESTIGATOR_307] (whichever comes 
first)  
The following assessments will be conducted on each  of Day  [ADDRESS_837748]: 
 
1. Vital signs (temperature/pulse/supi[INVESTIGATOR_050], if possible, blood pressure)  
2. Record  the usage of any concomitant medications  and ongoing treatments.  This  should 
include the following: 
a. Documentation of the standard of care 
b. The clinical rationale  for initiation  of mechanical  ventilation,  if necessary  
c. Documentation of supportive measures  for ARDS  (e.g., proning, paralytics, 
etc.) 
d. Care decisions  that are based  on limitations  of resources  at the clinical  site 
3. Adverse events  
4. Dose  study drug 
5. At the time of discharge from  the hospi[INVESTIGATOR_307], patients  should be advised  to use refrain 
from prolonged exposure to the sun or use at least SPF 50 on all exposed skin and 
protective clothing during prolonged sun exposure until the Day 60 adverse event assessment.  
 
8.5 Day 3, Day 9, and Day 15  
The following additional assessm ent will be conducted on Days  3, Day 9 and 15: 
 
1. SpO 2 level  (%) (or day of discharge if prior to  Day  15) 
2. Serum  Chemistry  – (Appendix A ) (or day of discharge if prior to Day 15) 
3. Hematology – ( Appendix A )  (or day of discharge if prior to Day 15) 
4. Viral  load (Day  9 only or day of discharge if prior to  Day  9) 
5. WHO  Ordinal Scale score assessment  (Day  15 only or day of discharge if prior to Day 15) 
6. Physical  examination  (including weight) (Day  15 only or day of discharge  if prior to Day 
15) 
7. Pregnancy  test (Day  15 only or day of discharge if prior to Day 15) (women  of 
childbearing potential only) 
8. 12 lead  ECG  (single) (Day 15 only or day of discharge if prior to  Day  15) 
9. Plasma  samples  for pharmacokinetic assessment  will be taken  prior to dosing on Day 3 
and Day 9. 
 
8.6 Day 22 ± 3 days (these  assessments will also be done  at Early  Termination  from  the 
study)  
The following assessments will be performed  on Day 22 (± 3 days):  
 
1. Vital Signs (temperature/pulse/supi[INVESTIGATOR_9204])  
2. SpO 2 level  (%) 
3. Physical  examination  (including weight)  
4. 12-lead ECG  (single)  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837749] scan 
6. Clinical Laboratory tests 
a. Hematology ( Appendix A ) 
b. Serum  chemistry  (Appendix A ) 
c. Urinalysis  
7. Adverse events  
8. Pregnancy  test (women  of childbearing potential only)  
9. Record  the usage of any concomitant  medications and  ongoing treatments.  
10. WHO  Ordinal Scale score assessment  (at Day 22 or  day of discharge if prior to Day 22) 
 
8.7 Day 29 ± 3 days  
The following assessments will be performed at  approximately  Day 29 (±  3 days):  
 
1. Vital Signs (temperature/pulse/supi[INVESTIGATOR_9204])  
2. SpO 2 level  (%) 
3. Physical  examination  (including weight)  
4. 12-lead ECG  (single)  
5. Chest  X-ray or CT scan 
6. Clinical Laboratory tests 
a. Hematology ( Appendix A ) 
b. Serum  chemistry  (Appendix A ) 
c. Urinalysis  
7. Adverse events  
8. Pregnancy  test (women  of childbearing potential only)  
9. Record  the usage of any concomitant  medications and  ongoing treatments.  
10. WHO  Ordinal Scale score assessment  (at Day 29 or  day of discharge if prior to Day 29) 
 
8.8 Follow up visits  at Day 45 (± 3 days) and Day 60 (± 3 days) (conducted  via 
phone/teleconference)  
1. Adverse e vents  
2. WHO  Ordinal Scale score assessment  
 
8.[ADDRESS_837750], this issue  should be discussed  with the 
Medical Monit or for this study and dosing may be discontinued. 
 
In subjects that experience an adverse event of Grade 4 or greater severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5 (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0_2010-06-14_QuickReference_5x7.pdf)  that 
is deemed to be possible, probably or definitely related to study drug dosing with study drug will be discontinued. Prior to discontinuation of study drug, the grading of the event and causal relationship should be discussed with the Medical Monitor for the study. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837751]  or ALT  levels  are >[ADDRESS_837752] or ALT levels are >3 times the upper limit of normal along with a  total 
bilirubin elevation of >2 times the upper limit of normal.  
 
Subjects will be discontinued from dosing if Grade 3 diarrhea is observed. 
Subjects  will be discontinued from  dosing if Grade 3 neutropenia is observed. 
NOTE: These subject stoppi[INVESTIGATOR_628616], not 
discontinuation from  the study. Subjects  should be followed for efficacy  and safety  even  if 
study drug is stopped based on these stoppi[INVESTIGATOR_004]. 
 
8.10 Early  Discontinuation of Study  Treatment  or Early  Termination  from  the Study  
Subjects  may prematurely  discontinue study treatment  for any of the following  reasons:  
 
1. Consent withdrawn  for further study treatment (specify  the reason).  
2. Significant and unacceptable adverse event  – specify  the adverse  event  leading  to 
discontinuation of study drug 
3. Investigator decision (specify  the reason),  must be approved by [CONTACT_46449]  
4. Non-compliance by [CONTACT_628638], must be approved by [CONTACT_22955]  
5. Lost to follow-up (record the  date of last contact)  
6. Death  (specify  the following information)  
a. Date of death  
b. Death  due to primary  disease? Yes  or no 
c. Death  due to study drug? Yes  or no 
d. Death  due to adverse event? Yes or no 
7. Lack  of efficacy  
8. Study terminated  by [CONTACT_1034]  
9. Other  r eason  (specify  the reason)  should be approved by [CONTACT_628639]. 
Subjects who discontinue study drug prematurely will not be replaced. At the time of discontinuation, please fill out the End of Study case report  forms  (eCRFs)  and subject 
disposition eCRF pages.  
 
Every  effort  will be made for the patient  to complete  all study related  procedures at Day 15, 
Day 22, Day 29, Day 45, and Day 60. Every effort will be made to determine patient status (alive  or dead) at Day 15, Day  22, Day  29, and  Day 60. This determination  can be made via 
telephone contact [CONTACT_628640]. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 26 -  
 OF NOTE:  For subjects  who are terminated  from  the study prematurely,  every  effort  should 
be made to have the subject complete all Early Termination Assessments (same as day 22 
assessments). The reason for early termination from the study will be documented for each subject. Subjects who are early terminations will not be replaced. At the time of early 
termination, please fill out the Early Termination and End of Study case report forms. 
 
Every  effort  should be made to determine  patient  status  (alive  or dead)  at Day  60. This 
determination can be made via telephone contact [CONTACT_628640]. 
 
8.11 Adverse Events  
An adverse  event  (AE) is any unfavorable or unintended change in body structure  (signs) or 
body function (symptoms), abnormal laboratory result that is associated with symptoms or requires treatment or worsening of a pre-existing condition. This includes all such events regardless of the presumed relationship between the event and the study medication(s). 
 
Any AE that occurs after the informed consent is signed but prior to dosing on Day [ADDRESS_837753] will be assessed for the development of any adverse events. Adverse events should be  assessed daily during the  time in the hospi[INVESTIGATOR_628617].  This  information  should be obtained in  the form  of non- leading  questions (e.g., 
"How are  you feeling?")  and from  signs and  symptoms  detected  during each  examination, 
observations of the study personnel or spontaneous reports from the subjects. 
 
Any AEs such as complaints, signs, or symptoms  that occur during the course of the  study or 
designated follow -up periods will be recorded on the subject's case report form (eCRF). This 
would include AEs  resulting from  concurrent illnesses,  reactions  to concomitant medications, 
or progressive disease states. 
 
Whenever  possible, the AE will be described  on the case report form  using standard  medical 
terminology consistent with Common Terminology Criteria for Adverse Events (CTCAE) version [ADDRESS_837754] medication, outcome and action taken. 
 
Each  AE will be evaluated  for duration, intensity,  and relationship  to (or association  with)  the 
study treatment (or other causes). Additionally, the actions taken (e.g., reduction of dosage, discontinuation of study medication, administration of treatment, etc.) and the resulting outcome of the AE will be indicated on the case report form. 
 
Any subject  who is withdrawn  from  the study drug due to an adverse event will be followed 
until the outcome of the event is determined, and the investigator will prepare a written  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 27 -  
 summary  of the event  and document the available follow-up information  on the case report 
form.  
 
8.11.1 Intensity  of Adverse Events  
The intensity  of the AEs will be graded  according to CTCAE  version 5. For any adverse event 
that is not specifically covered in CTCAE version 5, the following criteria should be used: 
 
Grade  Description  
 
1 Mild; asymptomatic  or mild symptoms; clinical  or diagnostic 
observations only; intervention not indicated 
 
2 Moderate;  minimal,  local  or noninvasive intervention indicated; 
limiting age -appropriate instrumental activities of daily living  
 
3 Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_231320];  disabling; 
limiting self -care activities of dai ly living  
 
4 Life-threatening consequences:  urgent intervention  indicated.  
 
5 Death  related  to AE 
 
If the intensity (Grade) changes within a day, the maximum intensity (Grade) should be 
recorded.  If the intensity  (Grade)  changes  over a longer period of time,  the changes  should be 
recorded as separate events (having separate onset and stop dates for each grade).  
 
8.11.[ADDRESS_837755] Medication  Causality  
The relationship  (or association)  of each AE to the test medication  will be assessed  by [CONTACT_70723]: 
 
Unrelated:  There is no chance that the study medication caused the AE; other conditions, 
including concurrent illnesses,  progression or expression  of the disease  state,  or a reaction  to a 
concomitant medication best explain the event.  
 
Unlikely:  There is little chance that the study medication caused the AE; other 
conditions, including concurrent  illnesses,  progression or expression of the disease state,  or a 
reaction to a concomitant medication best explain the event. 
 
Possible:  The association  of the AE with the study medication  is unknown; however, the 
AE is not clearly due to another condition. 
 
Probable:  A reasonable temporal association exists between the AE and treatment 
administration  and, based  on the investigator's clinical  experience,  the association  of the AE 
with the study treatment seems likely.  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 28 -  
 Definite:  The association  of the AE with the study medication  has a direct  relationship. 
 
For the purpose of safety  analyses,  all AEs which  are classified  as "Possible," "Probable" or 
“Definite” will be considered treatment -related events.  
 
8.11.3 Serious  Adverse Events  
A serious adverse event (SAE) is defined as any experience that su ggests a significant 
clinical  hazard,  contraindication, side effect,  or precaution. This includes any event  which: 
 
• Results  in death.  
• Is life-threatening.  
• Requires  inpatient hospi[INVESTIGATOR_292996]  
• Results  in persistent  or significant disability/incapacity.  
• Results  in congenital abnormality/birth  defect.  
• Requires  intervention to prevent  permanent  impairment or damage  
 
An SAE  also may  include other events,  based  on medical  judgment, which  jeopardize the 
subject and require  medical or surgical intervention to prevent one of  the outcomes listed 
above.  
 
Any SAE,  including death  due to any cause,  which  occurs  during the study or within [ADDRESS_837756] be reported  immediately  via telephone (within  24 hours) to Veru Inc.  Drug 
Safety.  
 
In addition, the investigator must immediately  complete a Serious Adverse Event eCRF  report 
form and electronically submit the form. The investigator will promptly notify the  
Institutional Review Board (IRB). 
 
If additional information  regarding a previously submitted  SAE  is obtained, a follow-up SAE 
eCRF report should be completed and submitted as indicated above. Supporting source documentation should be provided to  Drug Safety at the contact 
[CONTACT_31307]. 
 
 
 
 
 
 
 
 
 
 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837757] be reported to the 
Sponsor (or designee) within [ADDRESS_837758] medical practice. During the course of the study, the overall  safety,  and tolerability  of all study treatments  will be reviewed 
by [CONTACT_16998].  
 
8.11.6 Reporting  of Adverse  Events  Associated  with  Study  Drug  Overdose,  Misuse, 
Abuse or Medication Error  
AEs associated  with study drug overdose, misuse,  abuse,  and medication  error  refer to AEs 
associated with uses of the study drug outside of that specified by [CONTACT_760]. Overdose, misuse, abuse, and medication error are defined as follows: 
 
Overdose: Accidental  or intentional use of the study drug in an amount higher than the 
protocol- defined dose 
 
Misuse:  Intentional and  inappropriate use of study drug not in accordance with  the protocol  
 
Abuse: Sporadic or persistent  intentional excessive use of study drug accompanied  by [CONTACT_628641]: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 30 -  
 Medication  error:  Any unintentional event  that causes  or leads  to inappropriate study drug use 
or subject harm while the study drug is in the control of site personnel or the subject. 
 
All AEs associa ted with overdose, misuse, abuse, or medication error should be captured on 
the Adverse Event eCRF and also reported using the procedures detailed in Reporting of 
SAEs  even  if the AEs do not meet  serious criteria.  Abuse is always  to be captured  as an AE. If 
the AE associated with an overdose, misuse, abuse, or medication error does not meet serious criteria,  it must still be reported  using the SAE  form  and in an expedited  manner  but should be 
noted as non-serious on the SAE form and the Adverse Event eCRF. 
 
8.12 Concomitant Medications  and Concomitant Therapi[INVESTIGATOR_385059]  (including OTC  medications)  taken  by a subject  within  [ADDRESS_837759] will be instructed to report the use of any medication (including OTC medications) to the investigator. 
 
 
8.13 Prohibited  Medications  
The following medications  are prohibited with the appropriate washout period, if any, for 
each prohibited medication: 
 
• Retroviral/antiretroviral medications,  except  for remdesivir  
• Any experimental  drug/clinical trial,  except  for remdesivir  and convalescent plasma  
• colchicine  
8.14 Pharmacokinetic Sampling  and Handling  
The limited  sampling  schedule is used due to limitations  on study personnel entering  the 
patient’s room during the day. 
 
The blood sample  should be collected  in a 6 mL K2EDTA  blood collection  tube at each 
collection time.  
 
Immediately after collection, the tube will be gently inverted several times to mix the 
anticoagulant with the blood sample. The blood sample should be kept at room temperature until processed. The blood samples should be processed within 60 minutes after collection. The plasma fraction will be separated by [CONTACT_385078] a centrifuge for 10 minutes at 1,500 x g (at room temperature). The plasma fraction will be withdrawn by [CONTACT_21173][INVESTIGATOR_628618] (with each tube receiving approximately equal  aliquots). All plasma  samples  will be placed  into a freezer  at -20
oC (or below) within  90 
minutes after collection. (NOTE: A flash freezing in dry ice or liquid nitrogen is NOT required under this protocol but may be used.) 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 31 -  
 8.15 Plasma  Sample  Labels  for Pharmacokinetic Samples  
The plasma  freezing  tube labels will contain the following information:  
 
• Subject  Number  
• Study Number  
• Site Number  
• Prior Dosing time (hour and minute)  
• Sample  time (hour and minute)  
• Aliquot Number: Aliquot A or B 
• Species  and Matrix: Human  Plasma  
• Sample  Sequence Number  
• Barcode  Number  
Labels  will be fixed  to freezing  tubes in a manner  that will prevent the label  from  becoming 
detached after freezing.  
 
All plasma  samples  will be stored  frozen  (-20°C  or below). Details  of the method validation 
and sample analysis will be included with the final report. 
 
9.0 STATISTICAL  ANALYSIS  
 
9.1 Sample  Size Calculation  
In the Phase  2, the VERU-111 treated  group showed  a 5.3% mortality  rate compared  to a 30% 
mortality rate in the Placebo group in the same patient population. 
 
Approximately, 210 subjects are planned to be randomized at a 2:1 ratio into two treatment 
arms (140 subjects in the VERU-111 treated group and 70 subjects in the Placebo treated group). Randomization will be stratified  by [CONTACT_628642] 4, 5 and 6 
such that subjects  with a WHO  Ordinal Scale of 4, 5 and 6 at baseline will be  approximately 
equally distributed between the treatment groups. Assuming a rate of mortality of 5% in the VERU-111 treated  group and 25% in the Placebo treated group,  the above sample  sizes will 
yield 95% confidence interval of [ --0.308, -0.092] for the risk difference between treatment 
groups. Other scenarios are shown in the table below. 
 
Confidence interval = (p1 – p2) +/- z*√(p1(1 -p1)/n1 + p2(1-p2)/n2) 
where:  
• p1, p2: sample  1 proportion, sample 2 proportion  
• z: the z- critical value based  on the confidence level  
• n1, n2: sample  1 size, sample 2 size  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 32 -  
 Table of Alternative  95% Confidence intervals  for the difference between  Treatment  Groups: 
Mortality at Day 60  
 
 
VERU -111  
Placebo   
Difference   
LOWER  95%  CI  
UPPER  95%  CI 
0.05  0.15  -0.1 -0.191107629  -0.008892371  
0.05  0.2 -0.15  -0.250420118  -0.049579882  
0.05  0.25  -0.2 -0.307672652  -0.092327348  
0.05  0.3 -0.25  -0.363261644  -0.136738356  
0.1 0.15  -0.05  -0.147297482  0.047297482  
0.1 0.2 -0.1 -0.206067903  0.006067903  
0.1 0.25  -0.15  -0.262958399  -0.037041601  
0.1 0.3 -0.2 -0.318297929  -0.081702071  
0.15  0.15  0 -0.102449012  0.102449012  
0.15  0.2 -0.05  -0.160812454  0.060812454  
0.15  0.25  -0.1 -0.21742487  0.01742487  
0.15  0.3 -0.15  -0.27256998  -0.02743002  
 
With  significance level  α=0.05, and a 2:1 ratio of enrollment  into the VERU-111 and Placebo 
arms  respectively,  the sample  size is  adequate to  achieve >92% power assuming the treatment 
estimates stated above.  
 
NOTE:  The IDMC  will monitor efficacy  and safety  and may make a recommendation to stop 
the study based on treatment success according to the statistical analysis plan and IDMC 
charter for this study. 
 
9.2 Analysis Sets 
Intent -to-Treat  (ITT)  population: All  randomized subjects  will be included in this 
population.  
 
Modified  Intent -to-Treat  (mITT)  analysis set: All randomized  subjects who do not have 
any major protocol violations will be included in the mITT population. 
 
Safety  (SAF) analysis set: All randomized  subjects who  received  at least  one dose of study 
medication  (VERU -111 or Placebo)  will be included  in this population The SAF  population 
will be used as the safety population. 
 
9.3 Analysis Scope  
The Intent- to-Treat  (ITT)  analysis  scope will include all data collected  from  randomization to 
the end of the study at Day 60. This will be considered the primary analysis scope for the primary analysis. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 33 -  
 9.4 Efficacy  Analyses  
A statistical analysis  plan will be written  for this Phase  3 clinical  study. A detailed  description 
of the analyses that will be conducted will be included in that document. 
 
9.4.1 Primary  Endpoint  
The primary  endpoint for the study will be the proportion of subjects  that die on study (up to 
Day 60). 
 
The number and percentage of deaths will be summarized  by [CONTACT_2948]. Mortality  rates 
will be analyzed using a logistic regression model. This model will include treatment as a 
factor and study site, gender, remdesivir use (No/Yes), dexamethasone use (No/Yes) and WHO Ordinal Scale for Clinical Improvement at baseline as a covariates. The model will be fitted using logit link function. Odds ratios, standard errors, 95% confidence intervals and p- values for the treatment difference will be presented.  
 
The primary analysis will be performed on the ITT analysis set and the ITT data scope 
regardless of patient’s use of rescue medications, protocol violations or investigational product discontinuation consistent with the treatment policy strategy. Every effort will be made to collect  vital status  up to the end of the study  period. Missing  data for subjects  who 
are lost to follow up will be imputed using multiple imputation methods. Details for the imputation will be given in the Statistical Analysis Plan (SAP).  
 
9.4.2 Secondary  Analyses of the Primary  Endpoint  
The primary  endpoint, mortality  rate,  will also be assessed  in the subset of mITT  patients.  
 
To obtain risk differences  between  treatment groups, the same analysis  as described  above 
will be fitted except identity link function will be used.  
 
Additionally, mortality rates will be summarized using Kaplan -Meier (KM) survival curves 
and equality of treatment groups will be tested using log- rank test. Hazard ratios will be 
calculated  using the Cox proportional hazards  model  including terms  for treatment,  study site, 
gender, remdesivir use (No/Yes), dexamethasone use (No/Yes) and WHO Ordinal Scale for Clinical Improvement at baseline. Any subjects that are lost to follow -up or terminat ed early 
prior to death will be censored at the day of their last observed assessment or last captured event.  
 
[IP_ADDRESS] Sensitivity  Analyses  
A sensitivity  analysis  using the tippi[INVESTIGATOR_007]-point approach  will be conducted to assess the 
robustness of the primary analysis approach. 
 
Missing  endpoints will be re-assigned  in a series  of analyses  that are progressively more  in 
favor of placebo. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 34 -  
 The tippi[INVESTIGATOR_628619]. This will be done by [CONTACT_628643]  0% to 100% in a stepwise  manner.  The imputation  will 
be performed independently within the two treatment groups so that, in the most extreme case, the imputed response rate in the VERU -111 arm will be 0% and 100% in the placebo 
arm. 
 
Multiple  imputation  will be used for each  pair of response rates  under consideration. Both the 
imputation model and the analysis model will incorporate the covariates as used in the primary analysis. 
 
Details  for the imputation  will be given in  the SAP.  
 
9.5 Secondary  Endpoint  
Primary  analysis  of secondary  endpoints will be performed  on the ITT  analysis set and the 
ITT data scope regardless of patient’s use of rescue medications, protocol violations or investigational product discontinuation consistent with the treatment policy strategy. 
 
Full details  for the handling of missing  data,  and considerati on of subjects  that die during the 
study for those endpoints that do not directly incorporate death, will be included in the Statistical Analysis Plan.  
 
9.5.1 Proportion of patients  alive and free of respi[INVESTIGATOR_628607] 29, Day 15 and 
Day 22 
Respi[INVESTIGATOR_419918], extracorporeal  membrane  oxygenation, high- flow nasal  cannula oxygen delivery,  noninvasive 
positive pressure  ventilation, clinical  diagnosis of respi[INVESTIGATOR_628620].  
 
This analysis  will compare the percentage of subjects  that are alive  without respi[INVESTIGATOR_33078] 
(responder) on Day 29 and on Day 15 and on Day 22. 
 
Proportion of subjects alive and free of respi[INVESTIGATOR_628621] ( section  9.4.1).  
 
[IP_ADDRESS] Days in ICU 
Days  in ICU  will be summarized  using descriptive  statistics  (n, mean,  standard  deviation, 
median, minimum, and maximum) by [CONTACT_1570]. 
 
For subject  who die, days in ICU will be set to the worst  possible outcome (29 days) to give 
deaths unfavorable value in the analysis. 
 
Treatment  comparison will be based  on analysis  of covariance (ANCOVA)  model including 
treatment as a factor and study site, gender, remdesivir use (No/Yes), dexamethasone use 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 35 -  
 (No/Yes) and WHO Or dinal Scale for Clinical Improvement at baseline as covariates. 
Treatment  difference,  standard error,  95% confidence interval  and p-value will be presented.  
 
[IP_ADDRESS] Change from  baseline  in WHO Ordinal Scale for Clinical Improvement  at Day 
15, Day [ADDRESS_837760] 
possible outcome (8 – death) for the following planned timepoints  to give deaths  unfavorable 
value in the analysis. For subjects who are discharged early, or are otherwise having missing values, following timepoints use data from multiple imputation. Details for the imputation will be given in the SAP. 
 
WHO  Ordinal Scale for Clinical Improvement will be summarized  using frequencies  and 
percentages by [CONTACT_135355]. Also change from baseline will be summarized.  
 
Change from baseline will be analyzed as ordinal response using proportional odds logistic regression. Analysis will be performed separately for each timepoint (Day 15, Day 22, Day 29). Proportionality of odds will be tested  and if the proportionality assumption does not hold, 
then non- proportional odds model will be fitted. Model will include treatment as fixed effect 
and study site, gender, remdesivir use (No/Yes), dexamethasone use (No/Yes) and WHO Ordinal Scale for Clinical Improveme nt at baseline as covariate. Odds ratio, 95% confidence 
interval and p- value for the treatment difference will be presented. Distribution of change 
from baseline will be plotted in stacked bar plot by [CONTACT_11571]. 
 
Proportional (or non-proportional) odds model will be performed  only using the imputed  data 
to include all subjects in the analysis.  
 
Additionally, descriptive statistics (n, mean, standard deviation, median, minimum and maximum)  will be summarized  for absolute values  and chang e from  baseline by [CONTACT_29014]. 
 
Additionally, change from baseline will be analyzed using mixed model for repeated measures (MMRM) including treatment, visit and treatment-by- visit interaction as fixed 
effects and study site, gender, remdesivir use (No/Yes), dexamethasone use (No/Yes) and WHO  Ordinal Scale for Clinical Improvement at baseline as covariate.  The resulting  F-tests 
will be based on Kenward -Roger’s adjusted degrees of freedom. Least squares means, 
standard errors, 95% confidence intervals and p- values for treatments and treatment 
differences at each visit will be presented.  
 
MMRM analysis  will be performed  only using the imputed  data to include all subjects  in the 
analysis.  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 36 -  
 [IP_ADDRESS] Days on mechanical  ventilation  
Days  on mechanical  ventilation  will be summarized  using descriptive statistics  (n, mean, 
standard deviation, median, minimum and maximum) by [CONTACT_1570]. 
 
For subject who die, days on mechanical  ventilation  will be set to the worst  possible outcome 
(29 days) to give deaths unfavorable value in the analysis. 
 
Days  on mechanical  ventilation  will be analyzed  using the same methodology as for Days  in 
ICU ( section [IP_ADDRESS]).  
 
[IP_ADDRESS] Days in hospi[INVESTIGATOR_628622]  (n, mean,  standard  deviation, 
median, minimum and maximum) by [CONTACT_1570]. 
 
For subject  who die, days in hospi[INVESTIGATOR_628623] (29 days) to 
give deaths unfavorable value in the analysis. 
 
Days  in hospi[INVESTIGATOR_628624] (section 
[IP_ADDRESS] ). 
 
[IP_ADDRESS] Mean  change from  baseline  in Viral  load to Day 9 
The mean  change in viral load from baseline to  Day 9  will be  assessed.  
 
Descriptive  statistics  (n, mean,  standard deviation, median,  minimum and maximum)  will be 
summarized for absolute values, and change from baseline by [CONTACT_1570]. 
 
Change from  baseline will be analyzed  using the same methodology as for change from 
baseline in WHO score ( section [IP_ADDRESS]).  
 
9.6 Pharmacokinetic Analysis  
The pharmacokinetic samples  for assessment  of VERU-111 levels  will be taken  at baseline 
(prior to dosing on Day 1) and then prior to dosing on Days 3 and 9. 
 
An evaluation  of baseline  levels  versus effectiveness  of VERU-111 will be conducted.  
 
Pharmacokinetic concentration  data will be summarized  using descriptive statistics  (n, mean, 
standard  deviation, median,  minimum and  maximum).  CV%,  geometric mean,  geometric SD 
and geometric CV% will be presented.  
 
All PK data will be listed.  
 
9.7 Safety  Analysis  
The frequency  of adverse  events  (AEs) will be tabulated  by [CONTACT_628644]. The incidence of AEs and the maximum intensity and frequency of AEs will be 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837761] was on treatment is a new -onset AE (regardless of the 
intensity of the AE when the treatment was initiated).  
 
All laboratory results,  vital sign measurements,  and other safety  variables  will be summarized 
using appropriate descriptive statistics. Changes from baseline will be computed and will be summarized using appropriate descriptive statistics.  
 
A summary  of the number of subjects  developi[INVESTIGATOR_628625]  
≥3x ULN,  5x ULN,  and 10x ULN,  respectively  and a shift table  for individual subjects  shifts 
from baseline to maximum observed value by [CONTACT_17203]: <3x ULN, ≥3x ULN, ≥5x ULN and  
≥10x ULN will be provided. Additionally, a summary  of patients  that develop Drug  Induced 
Liver Injury by [CONTACT_25742]’s Law will be provided. 
 
Safety  data will be summarized  utilizing  the SAF analysis  set. 
 
9.7.1 Independent  Data  Monitoring  Committee  (IDMC)  
An Independent Data Monitoring Committee (IDMC) will review the unblinded safety data from  this Phase 3 study, including all SAEs,  approximately every  4 weeks.  The efficacy  data 
will be reviewed at the specified timepoint for the interim efficacy analysis when approximately 50% of the subjects have completed Day 60. 
 
The recruitment of this Phase  [ADDRESS_837762] dose. 
 
9.7.2 Interim  Analysis  
An efficacy interim analysis of the primary endpoint, all-cause mortality at Day 60, will be conducted when approximately 71.4% of the subjects (~150 subjects) have completed Day 60, died or withdrawn  for other reasons.  The first 150 patients  randomized  into the study will 
be included in the planned interim analysis. The interim and final analyses will follow an O’Brien -Fleming group sequential design, with a plan of stoppi[INVESTIGATOR_628626] -111. The criterion for 
efficacy at the interim analysis will be a two -sided 0.0160 p-value (a one-sided p-value 
<=0.0080 in  favor  of VERU-111). If the criterion  is not met,  the trial will continue, and  the 
final analysis will have  a criterion for efficacy of a two -sided p -value <=0.0452 (one -sided 
0.0226 in favor of VERU-111). 
 
In addition, an estimate of the conditional power that the trial will be positive (statistically significant difference  for final analysis)  will be provided to the IDMC  at regular  intervals.  If 
the conditional power is below 0.[ADDRESS_837763] termination for futility. However, this would not be a binding rule. Factors other than the conditional power will be considered by [CONTACT_628645] a whole after carefully evaluating 
various factors, including among others, enrolment rate and safety. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837764]  and Compliance  
The study will be conducted in accordance with the Code of Federal Regulations (21 CFR parts  50, 54, 56, 312, and 314), which  originates from  the ethical  principles laid  down in the 
Declaration of Helsinki. Good Clinical Practices (GCPs) and the policies a nd procedures of 
the Sponsor and/or its authorized  representative will also be followed. This clinical  trial will 
be overseen and managed by a contract research organization (CRO) and the Sponsor. The CRO  will be responsible for data management,  data handling, clinical  monitoring, statistical 
analysis, quality assurance and the final study report. The Sponsor will be responsible for project management of the CRO.  
 
Sponsor  Emergency  Contact  [CONTACT_5628]:  
 
 
Before initiating a trial, the Investigator/Institution should have written and dated 
approval/favorable opi[INVESTIGATOR_628627]  (IEC)/IRB  for the trial 
protocol/amendment(s), written informed consent form, any consent form updates, subject 
recruitment procedures (e.g., advertisements), any written information to be provided to subjects and a statement from the IEC/IRB that they comply with GCP requirements. The IEC/IRB approval must identify the protocol version as well as the documents reviewed. 
 
After IEC/IRB approval, changes will require a formal amendment. Once the study has started, amendments should be made only in exceptional circumstances. Changes that do not affect  subject  safety  or data integrity  are classified  as administrative  changes and generally  do 
not require ethical approval. If ethically relevant aspects are concerned, the IEC/IRB must be informed and, if necessary, approval sought prior to implementation. Ethical approval on administrative changes will be obtained if required by [CONTACT_5737]/site IEC /IRB.  
 
10.[ADDRESS_837765]’s LAR or impartial witness. Written informed consent must be obtained prior to the subject entering  the study (before  initiation  of any study- related  procedure and administration  of the 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837766] (IMP).  Sufficient  time will be allowed  to discuss any 
questions raised by [CONTACT_423]. 
 
The Sponsor will provide a sample  informed  consent form.  The final version -controlled form 
must be agreed  to by [CONTACT_628646]/IRB  and must contain  all elements  included in 
the sample form, in language readily understood by [CONTACT_423]. Each subject’s original 
consent form,  personally  signed and dated  by [CONTACT_628647]’s LAR, and by [CONTACT_28506], will be retained by [CONTACT_737]. The Investigator will supply all enrolled subjects with a copy of their signed informed consent.  
 
The consent form may need to be revised during the trial should important new information become available that may be relevant to the safety of the subject or as a result of protocol amendments. In this instance approval should always be given by [CONTACT_6179]/ IRB. It is the 
Investigator’s responsibility  to ensure that all subjects subsequently entered  into the study and 
those currently in the study sign the amended form. This is documented in the same way as previously described. Subjects who have completed the study should be informed of any new information that may impact on their welfare/wellbeing.  
 
The Investigator should, with  the consent of the subject,  inform  the subject’s primary 
physician about their participation in the clinical trial.  
 
10.3 Protocol Amendm ents 
In the event  that an amendment  to this protocol is required, it will be classified  into one of the 
following three categories: 
 
• Non-Substantial  Amendments  are those that are not considered  ‘substantial’ (e.g., 
administrative changes) and as such only need to be notified to the IECs/IRBs or Competent Authorities (CA) for information purposes. 
 
• Substantial  Amendments  are those considered ‘substantial’  to the conduct of the clinical 
trial where they are likely to have a significant impact on: 
 
- the safety  or physical or mental  integrity  of the subjects;  
- the scientific  value of the trial; 
- the conduct or management  of the trial; or 
- the quality  or safety  of the IMP used in the trial. 
 
Substantial amendments must be notified to the IECs/IRBs and CA. Prior to implementation, documented approval must be received from the IECs/IRBs. In the case of the CA in the EU member  states,  approval or ‘favorable opi[INVESTIGATOR_1649]’ can be assumed  if the 
CA has raised no grounds for non- acceptance during an allocated time period (to be 
confirmed with the Sponsor’s Regulatory Affairs (RA) representative) following acknowledgment of receipt of a valid application to make a substantial amendment. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 40 -  
 • Urgent  Amendments  are those that require urgent  safety  measures  to protect the trial 
subjects  from  immediate  hazard  and as such may be implemented  immediately  by [CONTACT_385087]/IRBs and CA notification, forthwith. 
 
10.[ADDRESS_837767] be documented and reported to the Sponsor using the appropriate electronic form to be supplied by [CONTACT_1034]. Deviations will be categorized  into minor deviations or major  deviations; definitions and examples  of deviations 
will be  provided by [CONTACT_1034]. The Sponsor will be  reviewing all deviations on an ongoing 
basis.  
 
10.5 Data  Handling  and Recordkeepi[INVESTIGATOR_007]  
10.5.1 Data  Handling  
Data will be recorded  at the site on the eCRF  and reviewed  by [CONTACT_628648] 
(CRA)  during monitoring visits.  The CRA  will verify  data recorded  in the EDC  system  with 
source documents. All corrections or changes made to any study data must be appropriately tracked in an audit trail in the EDC system. An eCRF will be consid ered complete when all 
missing,  incorrect,  and/or inconsistent data has been  accounted for  and electronically  signed 
by [CONTACT_385088]. 
 
Data will be processed  using a validated  computer system  conforming to regulatory 
requirements.  
 
10.5.[ADDRESS_837768] comply with Title 21 of the Code of Federal Regulations (21 CFR  Part 11) and other appropriate international regulations. All passwords 
will be strictly confidential.  
 
10.5.3 Medical  Information Coding  
For medical  information,  the following thesauri  will be used:  
• Latest  version of MedDRA  (version  18.1 or higher) for medical  history and AEs, and 
• World  H ealth  Organization  Drug  Dictionary  Enhanced  (Sept.  2015 or later)  for prior and 
concomitant medications.  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837769] be kept in the appropriate study files at the site. Source data is defined as all information in original records and certified copi[INVESTIGATOR_34504], observations, or other activities in a clinical study necessary for the evaluation and reconstruction of the clinical study. Source data are contained in source documents (original records or certified copi[INVESTIGATOR_014]).  These records  will be retained  in a secure file for the period as set forth  in the Clinical 
Study Agreement. Prior to transfer or destruction of these records, the Sponsor must be notified in writing a nd be given the opportunity to further store such records. 
 
10.6 Data  Quality  
Monitored eCRFs  transferred  from  the investigational site  to the assigned  Data Management 
group will be reviewed  (secondary  monitoring) for completeness,  consistency,  legibility  and 
protocol compliance. 
 
Reasons should be given on the relevant eCRF for any missing data and other protocol deviations. Any electronic queries and items not adequately explained will require additional electronic manual queries to be raised to the Investigator by [CONTACT_223064]/correction.  The Investigator must ensure that queries  are dealt  with  promptly. All 
data changes and clarifications can be viewed in the audit trail function of the eCRF. 
 
Clinical site personnel must make themselves available for  any potential audit by [CONTACT_628649], such as, but not limited to, [LOCATION_002] 
Food and  Drug  Administration.  The clinical  site personnel must be completely  responsive and 
cooperative during these audits. 
 
10.7 Regulatory Approval  
As required by [CONTACT_427], the Sponsor’s Regulatory Affairs group will ensure all legal regulatory aspects  are covered,  and obtain approval of the appropriate regulatory  bodies, prior 
to study initiation in regions where an approval is required.  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 42 -  
 10.8 Publication  Policy  
The Sponsor encourages acknowledgement of all individuals/organizations involved in the 
funding or conduct of the study, including medical writers or statisticians subject to the consent of each individual and entity  concerned,  including acknowledgement of the Sponsor. 
 
The results of this study may be published or communicated to scientific meetings by [CONTACT_486015]. For multicenter studies, a plan for scientific publication 
and presentation  of the results  may be agreed  and implemented  by [CONTACT_385092] a 
Steering Committee. The  Sponsor requires that reasonable opportunity be given to review the 
content and conclusions of any abstract, presentation, or paper before the material is submitted for publication or communicated. This condition also applies to any amendments that are subsequently requested by [CONTACT_385093]. The Sponsor will undertake to comment on the draft documents within the time period agreed in the contractual arrangements, including clinical trial agreements, governing the relationship between the Sponsor and authors (or the author’s institution).  Requested  amendments will be incorporated 
by [CONTACT_347230], provided they do not alter the scientific value of the material. 
 
If patentability  would be adversely  affected  by [CONTACT_325582], this will be delayed  until (i) a 
patent  application  is filed for the content of the publi cation  in accordance with applicable 
provisions of the clinical trial agreement concerned, (ii) the Sponsor consents to the publication, or (iii) the time period as may be agreed in the contractual arrangements, including clinical trial agreements, governing the relationship between the Sponsor and authors (or authors’ institution) after receipt of the proposed publication by [CONTACT_1034], whichever of (i), (ii) or (iii) occurs first.  
 
The author undertakes  to reasonably  consider the Sponsor's request  for delay  to the proposed 
publication should the Sponsor reasonably deem premature  to publish the  results obtained at 
the then stage of the study. 
 
10.[ADDRESS_837770] has signed informed consent, regardless of whether the trial is completed or prematurely terminated. Where appropriate an abbreviated report may be prepared. The CSR 
will be in compliance with any applicable regulatory requirements,  national laws  in force and 
will be in English.  
 
10.10 Contractual and Financial Details  
The Investigator (and/or, as appropriate, the hospi[INVESTIGATOR_307]/institution  authorized  representative)  and 
the Sponsor will sign a clinical study agreement prior to the start of the study, outlining overall Sponsor and Investigator responsibilities in relation to the study. Financial remuneration will cover the cost per included subject, based on the calcul ated costs of 
performing  the study assessments  and other activities  in accordance with  the protocol, and the 
specified terms of payment will be described in the contract. The contract should describe 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837771] of microtubule disruption on neuronal spread and replication of 
demyelinating  and nondemyelinating strains  of mouse  hepatitis  virus in vitro. J Virol  88:3-43- 
3047, 2014. 
 
Burkard  C et al. Coronavirus cell entry  occurs  through the endo-/lysosomal pathway  in a 
proteolysis-dependent manner. PLOS Pathogens 10:e1004502, 2014. 
 
Cascella M. et al. Features,  evaluation, and treatment coronavirus (COVID -19) StatPearls 
2020 www.ncb i.nlm.nih.gov/books/NBK554776. 
 
Chen  J et al. Discovery of novel 2- aryl-4-benzoyl- imidazole  (ABI -III) analogues  targeting 
tubulin polymerization as antiproliferative agents. J Med Chem 55:7285-7289, 2012. 
 
Cooper GM. The Cell: A Molecular  Approach.2nd edition. Sunderland(MA): Sinauer 
Associates 2000. Microtubules. https://www.ncbi.nlm.nih.gov/books/NBK9932. 
 
Criglar  JM et al. A novel form  of rotavirus NSP2  and phosphorylation-dependent NSP2 - 
NPS5 interactions are associated with viroplasm assembly. J Virol 88:786-798, 2014. 
 
Dohner K et  al. Viral  stop- and-go along microtubules: taking a ride with dynein and kinesins. 
Trends in Microbiology 13:320-327, 2005. 
 
Eichwald  C et al. Rotavirus viroplasm fusion and perinuclear  localization  are dynamic 
processes requiring stabilized microtubules. PLoS One 7:e47947, 2012. 
 
Fung S et al. Human  Coronavirus: host-pathogen interaction.  Annu Rev Microbiol 73:529-57, 
2019.  
 
Gorbalenya AE et al. The species  severe acute respi[INVESTIGATOR_7497]- related  coronavirus: 
classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020. 
 
Han X et al. Influenza virus A/Beijing/501/2009 (H1N1) interacts with beta tubulin and induces disruption of the microtubule network and apoptosis on A549 cells.  PLoS  One:7, 
e48340, 2012. 
 
Hara Y et al. Propagation of swine  hemagglutinating encelphalomyelitis  virus and 
pseudorabies virus in dorsal root ganglia cells. J Vet Med Sci 71:595-601, 2009. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) [ADDRESS_837772] promotes, but is not required for, 
severe acute  respi[INVESTIGATOR_628628]-induced remodeling 
of endoplasmic reticulum membranes. J Virol 84:833-846, 2010. 
 
Li CM et al. Orally  bioavailable  tubulin antagonists for paclitaxel -refractory  cancer.  Pharm 
Res 29:3053-3063, 2012. 
 
Lv et al. Porcine hemagglutinating encephalomyelitis virus activation of the integrin a5b1- 
FAK -cofilin  pathway  causes  cytoskeleton rearrangement  to promote its invasion of N2a cells. 
J Virol 93:1-19, 2019. 
 
Milewski  A et al. Entry  of human coronavirus NL63  into the cell. J Virology 92:e01933-17, 
2018.  
 
Naghavi MH et al. Microtubule regulation and function during virus infection. J Virol 
91:e00538-17, 2017. 
 
Oostra  M et al. Localization  and membrane topology of coronavirus nonstructural protein. 4: 
involvement of the early secretory pathway in replication. J Virol 81:[ZIP_CODE]-[ZIP_CODE], 2007. 
 
Ren et al. Genetic drift of human coronavirus OC43  spi[INVESTIGATOR_419936]. 
Scientific Reports 5:[ZIP_CODE], 2015. 
 
Rudiger AT et al. Tubulins interact with porcine and human S proteins of the genus alphacoronavirus and support successful  assembly  and release of infectious  viral particles. 
Virology 497:185-197, 2016. 
 
Simpson C et al. Microtubules in influenza virus entry  and egress.  Viruses  12:117, 2020. 
Slobodnick A et al. Update on colchicine, 2017. Rheumatology 57:i4-i11, 2018. 
Suomalainen  M et al. Adenovrius- activated  PKA and p38/MAPK pathways  boost 
microtubule-mediated nuclear targeting of virus. EMBO J 20 :1310-1319, 2001. 
 
Verweyen  E et al. Synergistic  signaling of TLR  and IFN alpha/beta facilitates  escape of IL -18 
expression from endotoxin tolerance. American J Resp and Critical Care Medicine 201:526- 
539, 2020. 
 
Ward  B. The taking of the cytoskeleton one two three:  How viruses utilize  the cytoskeleton 
during egress. Virology 411:244-250, 2011. 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
 Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 45 -  
 12.0 APPENDICES  
 
12.1 Appendix  A: Clinical Laboratory Tests  (local laboratory)  
 
Hematology:  Serum  Chemistry:  
Hemoglobin  Sodium  
Hematocrit  Potassium  
Red Blood  Cell Count  Chloride  
White  Blood  Cell Count  Bicarbonatea 
White  Blood  Cell Differential  BUN  
Platelet  Count  Creatinine  
Reticulocyte  Count  Calcium  
Cardiac  Troponin  Phosphorus  
 Total  Protein  
Urinalysis:  Albumin  
pH Total  Bilirubin  
Specific  Gravity  SGOT  (ALT)  
Protein  SGPT  (AST)  
Glucose  Alkaline  phosphatase  
Leucocytes  LDH  
Nitrates  GGT  
Ketones  Glucose  
Blood  Ferritin  
Microscopic  Examination  (only  if urinalysis  results  are 
abnormal)  D-dimer  
a Bicarbonate will be collected  only if it is part of the standard  local  panel. 

FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  - 46 -  
 DocuSign Envelope ID: 103C243F -9939 -4811- B616 -1FEA4EC66A87  
 
 
Veru  Inc C
Protocol  V3011902 – FINAL  Version 7.0 
 
12.2 Appendix  B: Schedule  of Study  Evaluations  
 
Day Screena Day 1 Days  2-21 Days  3, 9, & [ADDRESS_837773] X X  Xf X  
Vital  signs  X X X  X  
12-lead ECG  (single)  X   Xf X  
WHO  Ordinal  Scale  score  X X  Xf X X 
Chest  X-ray or CT  X   X  
Clinical  Laboratory  Tests        
Hematology  X X  X X  
Urinalysis  X X   X  
Serum  Chemistry  X X  X X  
SpO [ADDRESS_837774]  the study  assessments as outlined  herein.  
d Early  termination  assessments  are the same  as Day 22 assessments 
e Days  3 and  9 only 
f Day 15 only 
g Day 9 only (or day of discharge  if prior  to Day 9) 

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
C Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 47 -  
 
 
PROTOCOL  SIGNATURE  [CONTACT_118258]:  V3011902  
 
Protocol Date:  Protocol Amendment 6 (Version  7.0)/ 18 March  2022  
 
Protocol Title: Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety 
Study of VERU-111 for the Treatment  of Severe Acute Respi[INVESTIGATOR_81370] 2 (SARS-CoV- 2) in Patients at High Risk 
for Acute Respi[INVESTIGATOR_39053] (ARDS) 
 
 
 
 
SIGNATURE:  
 
3/18/2022  
 
Sponsor  Date 
 
  
Chief Scientific  Officer 
 
 
Name  [CONTACT_628650].  

DocuSign  Envelope  ID: 103C243F -9939 -4811 -B616 -1FEA4EC66A87  
C Veru  Inc 
Protocol  V3011902  – FINAL  Version  7.0 
FINAL:  Protocol  Amendment  6 (Version  7.0) 18 March  2022  
- 48 -  
  
PRINCIPAL  INVESTIGATOR  [INVESTIGATOR_628629]:  V3011902  
 
Protocol Title: Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety 
Study of VERU-111 for the Treatment  of Severe Acute Respi[INVESTIGATOR_81370] 2 (SARS-CoV- 2) in Patients at High Risk 
for Acute Respi[INVESTIGATOR_39053] (ARD S) 
 
Protocol Date:  Protocol Amendment 6 (Version  7.0)/ 18 March  2022  
  
 
 
SIGNATURE:  
    
 
[CONTACT_270511] : [INVESTIGATOR_628630] (Please Print)  
 
   
 
Address  of Principal  Investigator  
  
 
[INVESTIGATOR_628631] (GCP). 
